Eli Lilly has received marketing authorization from India's Central Drugs Standard Control Organization for donanemab, its treatment for early symptomatic Alzheimer's disease. This approval allows Lilly to enter a significant new market with a high unmet need, as India's aging population faces a growing dementia challenge. Separately, JPMorgan raised its price target on Eli Lilly stock to $1,150 from $1,050, maintaining an Overweight rating. The investment bank's positive outlook is based on the continued market share gains of its popular obesity and diabetes drugs and the large, underpenetrated international market for these treatments. These developments follow a period of strong performance for Lilly's stock, fueled by robust sales of its key drugs.